Literature DB >> 28251277

Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis.

T J Oscanoa1,2, F Lizaraso3, Alfonso Carvajal4,5.   

Abstract

INTRODUCTION: It is currently admitted that adverse drug reactions (ADRs) account for a great burden of disease. Of particular concern are ADR-induced hospital admissions, particularly in the elderly; they receive most of the medications and they are the most prone to develop ADRs. Therefore, our aim was to carry out a study of ADR-induced hospital admissions focused on the elderly population.
METHODS: For the purpose, a systematic review and meta-analysis was performed of those studies addressing ADR-induced hospital admissions in patients over 60 years of age. A computerized search of the literature was carried out in the main databases. The search spans from 1988 to 2015. A pooled prevalence figure was calculated with 95% CIs; heterogeneity was also explored.
RESULTS: The final number of selected articles was 42; all of them were published between January 1988 and August 2015. The overall average percentage of hospital admissions was 8.7% (95% CI, 7.6-9.8%). NSAIDs are one of the medication classes more frequently related to these admissions (percentages range from 2.3 to 33.3%). Inappropriate medication as a risk factor was studied in nine studies, four found a statistically significant relationship between those medications and hospital admissions.
CONCLUSIONS: Circa one in ten hospital admissions of older patients are due to ADRs. A great burden of disease is due to a few and identifiable medication classes; in most of the cases, the reactions are well known and probably preventable. A sense of purpose and determination is needed by health authorities to face this problem. Doctors, on their part, should be aware when prescribing some specific identifiable medications to these patients. KEY POINTS: 1. One in ten hospital admissions in older patients are due to ADRs; NSAIDs are the medications the most related with these admissions, followed by other common medications used in patients of this age, such as beta-blockers. 2. A great burden of disease is due to medications that are intended to cure or alleviate disease; this burden of disease is not only painful for the patients but also costly. 3. Identified risk factors are particular medication classes and polymedication. In most of the cases, reactions are probably preventable.

Entities:  

Keywords:  ADRs; Elderly patients; Hospital admissions; Meta-analysis

Mesh:

Year:  2017        PMID: 28251277     DOI: 10.1007/s00228-017-2225-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  73 in total

1.  Suspected adverse drug events requiring emergency department visits or hospital admissions.

Authors:  R Raschetti; M Morgutti; F Menniti-Ippolito; A Belisari; A Rossignoli; P Longhini; C La Guidara
Journal:  Eur J Clin Pharmacol       Date:  1999-02       Impact factor: 2.953

2.  Characterization of drug-related problems in elderly patients on admission to a medical ward.

Authors:  B J Courtman; S B Stallings
Journal:  Can J Hosp Pharm       Date:  1995-06

3.  Risk factors associated with adverse drug events among older adults in emergency department.

Authors:  Yen-Chia Chen; Ju-Sing Fan; Min-Hui Chen; Teh-Fu Hsu; Hsien-Hao Huang; Kuo-Wei Cheng; David Hung-Tsang Yen; Chun-I Huang; Liang-Kung Chen; Chen-Chang Yang
Journal:  Eur J Intern Med       Date:  2013-11-04       Impact factor: 4.487

4.  Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: A prospective, descriptive, observational study.

Authors:  Agnes L F Chan; Haw Yu Lee; Chi-Hou Ho; Thau-Ming Cham; Shun Jin Lin
Journal:  Curr Ther Res Clin Exp       Date:  2008-04

5.  National surveillance of emergency department visits for outpatient adverse drug events.

Authors:  Daniel S Budnitz; Daniel A Pollock; Kelly N Weidenbach; Aaron B Mendelsohn; Thomas J Schroeder; Joseph L Annest
Journal:  JAMA       Date:  2006-10-18       Impact factor: 56.272

Review 6.  Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.

Authors:  Jingjing Zhang; Eric L Ding; Yiqing Song
Journal:  JAMA       Date:  2006-09-12       Impact factor: 56.272

7.  Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes.

Authors:  Hanna E Bloomfield; Ange Krause; Nancy Greer; Brent C Taylor; Roderick MacDonald; Indulis Rutks; Preetham Reddy; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2011-04-05       Impact factor: 25.391

8.  Socio-demographic factors related to the prevalence of adverse drug reaction at hospital admission in an elderly population.

Authors:  Francisco Caamaño; Claudio Pedone; Guiseppe Zuccalà; Pierugo Carbonin
Journal:  Arch Gerontol Geriatr       Date:  2005 Jan-Feb       Impact factor: 3.250

Review 9.  Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies.

Authors:  Chuenjid Kongkaew; Peter R Noyce; Darren M Ashcroft
Journal:  Ann Pharmacother       Date:  2008-07-01       Impact factor: 3.154

10.  Adverse drug reactions and impaired renal function in elderly patients admitted to the emergency department: a retrospective study.

Authors:  Anders Helldén; Ulf Bergman; Mia von Euler; Maria Hentschke; Ingegerd Odar-Cederlöf; Gunnar Ohlén
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more
  72 in total

1.  Healthcare professionals' knowledge, attitude and practice towards adverse drug reaction (ADR) reporting at the health center level in Ethiopia.

Authors:  Mohammed Assen Seid; Asmamaw Emagn Kasahun; Bamlak Markos Mante; Saron Naji Gebremariam
Journal:  Int J Clin Pharm       Date:  2018-08-09

2.  Polypharmacy in Multiple Sclerosis: Current Knowledge and Future Directions.

Authors:  Joanie Thelen; Valeriy Zvonarev; Sarah Lam; Crystal Burkhardt; Sharon Lynch; Jared Bruce
Journal:  Mo Med       Date:  2021 May-Jun

3.  Prescription Medication Use in Older Adults Without Major Cardiovascular Disease Enrolled in the Aspirin in Reducing Events in the Elderly (ASPREE) Clinical Trial.

Authors:  Jessica E Lockery; Michael E Ernst; Jonathan C Broder; Suzanne G Orchard; Anne Murray; Mark R Nelson; Nigel P Stocks; Rory Wolfe; Christopher M Reid; Danny Liew; Robyn L Woods
Journal:  Pharmacotherapy       Date:  2020-10       Impact factor: 4.705

4.  Mortality among patients due to adverse drug reactions that occur following hospitalisation: a meta-analysis.

Authors:  Parvati B Patel; Tejas K Patel
Journal:  Eur J Clin Pharmacol       Date:  2019-06-11       Impact factor: 2.953

Review 5.  Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines.

Authors:  Silvio Garattini; Vittorio Bertele'
Journal:  Eur J Clin Pharmacol       Date:  2017-11-27       Impact factor: 2.953

Review 6.  Update on Medication Use Quality and Safety in Older Adults, 2017.

Authors:  Shelly L Gray; Zachary A Marcum; Kenneth E Schmader; Joseph T Hanlon
Journal:  J Am Geriatr Soc       Date:  2018-11-13       Impact factor: 5.562

Review 7.  The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis.

Authors:  Outi Laatikainen; J Miettunen; S Sneck; H Lehtiniemi; O Tenhunen; M Turpeinen
Journal:  Eur J Clin Pharmacol       Date:  2017-09-05       Impact factor: 2.953

8.  Reducing hospital admissions for adverse drug events through coordinated pharmacist care: learning from Hawai'i without a field trip.

Authors:  Michael A Steinman
Journal:  BMJ Qual Saf       Date:  2018-11-24       Impact factor: 7.035

9.  Meta-analysis of Interventions to Reduce Adverse Drug Reactions in Older Adults.

Authors:  Shelly L Gray; Laura A Hart; Subashan Perera; Todd P Semla; Kenneth E Schmader; Joseph T Hanlon
Journal:  J Am Geriatr Soc       Date:  2017-12-19       Impact factor: 5.562

10.  Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis.

Authors:  Tejas K Patel; Parvati B Patel
Journal:  Eur J Clin Pharmacol       Date:  2018-03-19       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.